The system provides an estimate of in vivo efficacy of commonly used antiretroviral drug combinations based on user-defined information of HIV genotype (mandatory) and additional patient information (recommended). The engine is not intended as a replacement for standard of care but can be used by HIV specialists as an additional treatment decision support tool. Although analysis of a large data set of medical records has shown a good performance of the system, there is no warranty that its use will improve patient health. HIV care must rely on a solid knowledge of the complex host-virus interaction and proper consideration of patient status and commitment.
The EuResist Integrated DataBase (EIDB) was set up to develop the EuResist prediction system. The EIDB is probably the largest European data set of genotype-response data suitable for training genotype-centered treatment respoense models.
The EIDB includes information about patients, drug therapies, AIDS defining events, CD4 and viral load measurements and HIV genomic sequences. As of June 2008 it contained 18,467 patients, 64,864 therapies, 22,006 HIV sequences, 240,795 viral load and 304,838 CD4 measurements.
The EIDB integrates biomedical information from the three founding national databases: the ARCA database (Italy: 10,984 patients, 41,570 therapies, 17,774 sequences), the AREVIR database (Germany: 2,444 patients, 6,154 therapies, 2,177 sequences), and data coming from Karolinska Institute (Sweden: 4,524 patients, 15,425 therapies, 1,095 sequences). The original data set is continuously updated with new data in order to improve the results of the prediction system. Following the EIDB setup, data from the Laboratoire de Rétrovirologie of CRP-Santé (Luxembourg: 515 patients, 1.715 therapies, 960 sequences) have also been uploaded.
You can contribute your data to the EuResist initiative and have the possibility to query the whole data set for study proposals (upon request). In order to facilitate the entry of additional data providers, general rules for participation have been agreed upon as follows.